Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Lazertinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 317,623Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CHMP Recommends Rybrevant & Lazcluze® for EGFR-mutant NSCLC
    CHMP Recommends Rybrevant & Lazcluze® for EGFR-mutant NSCLC

    15 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/15/2982110/0/en/CHMP-recommends-RYBREVANT-amivantamab-in-combination-with-LAZCLUZE-lazertinib-for-the-first-line-treatment-of-patients-with-EGFR-mutated-advanced-non-small-cell-lung-cancer.html

    GLOBENEWSWIRE
    15 Nov 2024
    Share Share
    J&J Bolsters Rybrevant-Lazcluze Case Vs AZ's Tagrisso With Survival Data
    J&J Bolsters Rybrevant-Lazcluze Case Vs AZ's Tagrisso With Survival Data

    09 Sep 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/jj-bolsters-rybrevant-lazcluzes-case-against-azs-tagrisso-nominal-survival-win

    FIERCE PHARMA
    09 Sep 2024
    Share Share
    RYBREVANT Plus Lazertinib Shows Survival Trend In Lung Cancer
    RYBREVANT Plus Lazertinib Shows Survival Trend In Lung Cancer

    08 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/08/2942454/0/en/RYBREVANT-amivantamab-plus-lazertinib-show-strong-favourable-overall-survival-trend-versus-osimertinib-in-EGFR-mutated-advanced-lung-cancer.html

    GLOBENEWSWIRE
    08 Sep 2024
    Share Share
    LAZCLUZE Now Available From Onco360 For Metastatic NSCLC Treatment
    LAZCLUZE Now Available From Onco360 For Metastatic NSCLC Treatment

    30 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/30/2938443/0/en/LAZCLUZE-lazertinib-Now-Available-from-Onco360-for-the-First-line-Treatment-in-Combination-with-Rybrevant-of-Adult-Patients-with-Metastatic-Non-Small-Cell-Lung-Cancer-Whose-Tumors-.html

    GLOBENEWSWIRE
    30 Aug 2024
    Share Share
    FDA Roundup: August 20, 2024
    FDA Roundup: August 20, 2024

    20 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fda-roundup-august-20-2024-302226711.html

    PR NEWSWIRE
    20 Aug 2024
    Share Share
    PALOMA-2: Subcutaneous RYBREVANT Combo Shows Response, Safety In EGFR+ NSCLC
    PALOMA-2: Subcutaneous RYBREVANT Combo Shows Response, Safety In EGFR+ NSCLC

    03 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/03/2892527/0/en/Late-breaking-results-from-PALOMA-2-study-of-subcutaneous-RYBREVANT-amivantamab-in-combination-with-lazertinib-show-clinically-meaningful-antitumour-response-and-improved-safety-pr.html

    GLOBENEWSWIRE
    03 Jun 2024
    Share Share